Latest / Clearly Hormonal / PCOS is Now PMOS: What the Name Change Means for Every Era of Your Hormonal Life

Transcript

PCOS is Now PMOS: What the Name Change Means for Every Era of Your Hormonal Life · Clearly Hormonal

• 0:06
  Dr. Komal Patil-Sisodia: ​Welcome to Clearly Hormonal, the podcast where we stop googling our symptoms at midnight and actually start understanding what's going on in our bodies.
• 0:14
  Dr. Komal Patil-Sisodia: I'm Dr.
• 0:15
  Dr. Komal Patil-Sisodia: Komal Patil-Sisodia, an endocrinologist, internist, obesity medicine specialist, and a Menopause Society certified practitioner, which is really just a whole lot of words to say hormones are kind of my jam.
• 0:26
  Dr. Komal Patil-Sisodia: I've spent 17 years watching women try to navigate their hormonal health without ever having been taught the language for what's happening in their own bodies, and then meeting clinicians who want nothing more than to help them figure it out, but are up against 10-minute appointments and a system that just wasn't built for it.
• 0:42
  Dr. Komal Patil-Sisodia: This podcast is my answer to that gap.
• 0:45
  Dr. Komal Patil-Sisodia: We'll cover menopause, metabolism, hormones, and everything in between with real evidence, not trends, and without the overwhelm.
• 0:53
  Dr. Komal Patil-Sisodia: A quick disclaimer.
• 0:54
  Dr. Komal Patil-Sisodia: I'm a physician, but this is education, not personalized medical advice.
• 0:58
  Dr. Komal Patil-Sisodia: Take what resonates and discuss it with your own healthcare team.
• 1:01
  Dr. Komal Patil-Sisodia: Now, let's get into it and talk about what's clearly hormonal and what's not.
• 1:08
  Dr. Komal Patil-Sisodia: Hey everyone.
• 1:08
  Dr. Komal Patil-Sisodia: Welcome back to Clearly Hormonal.
• 1:10
  Dr. Komal Patil-Sisodia: I'm your host, Dr.
• 1:11
  Dr. Komal Patil-Sisodia: Komal Patil-Sisodia, and today I want to talk about something that landed on May 12th, 2026 that genuinely stopped me in my tracks.
• 1:20
  Dr. Komal Patil-Sisodia: PCOS has a new name.
• 1:22
  Dr. Komal Patil-Sisodia: Polycystic Ovarian Syndrome is now officially published in The Lancet, Polyendocrine Metabolic Ovarian Syndrome.
• 1:31
  Dr. Komal Patil-Sisodia: PMOS, one letter, C to M.
• 1:35
  Dr. Komal Patil-Sisodia: And I know what you might be thinking, a name change?
• 1:38
  Dr. Komal Patil-Sisodia: That's big news?
• 1:39
  Dr. Komal Patil-Sisodia: But I want you to stay with me because in medicine, what we call something determines everything that happens next.
• 1:46
  Dr. Komal Patil-Sisodia: Who gets diagnosed, how they get treated, how seriously they're taken, and what their future looks like.
• 1:52
  Dr. Komal Patil-Sisodia: For the over one hundred seventy million women worldwide living with this condition, most of whom have never even received a correct diagnosis, that name has been doing real damage for a long time.
• 2:05
  Dr. Komal Patil-Sisodia: Today, I want to walk you through what changed, why it matters, and I want to do it in a way that I think will hit differently.
• 2:12
  Dr. Komal Patil-Sisodia: Because this condition doesn't live only in one chapter of a woman's life.
• 2:16
  Dr. Komal Patil-Sisodia: It shows up in every era, in adolescence, in the reproductive years, in perimenopause, and in menopause and beyond.
• 2:24
  Dr. Komal Patil-Sisodia: And what gets missed in each of those eras because of the wrong name, the wrong framing, the wrong questions being asked, compounds over a lifetime.
• 2:34
  Dr. Komal Patil-Sisodia: So that's how we're gonna tell this story today, era by era.
• 2:39
  Dr. Komal Patil-Sisodia: Before we go era by era, let's establish what actually happened and why the old name was so problematic.
• 2:46
  Dr. Komal Patil-Sisodia: The paper published in The Lancet is a result of fourteen years of global effort led by Professor Helena Teede at Monash University in Australia.
• 2:56
  Dr. Komal Patil-Sisodia: The process involved fifty-six leading academic, clinical, and patient organizations, including The Endocrine Society.
• 3:03
  Dr. Komal Patil-Sisodia: They gathered over twenty-two thousand survey responses from patients and clinicians across every world region.
• 3:10
  Dr. Komal Patil-Sisodia: This is the largest and most rigorous medical renaming process in history, and the conclusion was unambiguous.
• 3:18
  Dr. Komal Patil-Sisodia: The old name, polycystic ovarian syndrome, is scientifically inaccurate, and that inaccuracy has caused real harm.
• 3:27
  Dr. Komal Patil-Sisodia: The Lancet paper states directly that PCOS was, quote,"Inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and contributing to delayed diagnosis, fragmented care, and stigma, while curtailing research and policy framing." End quote.
• 3:46
  Dr. Komal Patil-Sisodia: Let me translate that into plain language.
• 3:49
  Dr. Komal Patil-Sisodia: The name told doctors and patients that this was a condition about ovarian cysts, and because cysts were the headline, everything else got minimized.
• 4:00
  Dr. Komal Patil-Sisodia: The insulin resistance, the androgen dysregulation, the cardiovascular risk, the metabolic consequences that build quietly over decades.
• 4:10
  Dr. Komal Patil-Sisodia: And in a related paper from the same research group, they confirmed what many of us have known clinically for years.
• 4:18
  Dr. Komal Patil-Sisodia: There is no significant increase in pathologic ovarian cysts in this condition.
• 4:24
  Dr. Komal Patil-Sisodia: The follicles visible on ultrasound reflect disrupted ovulation.
• 4:29
  Dr. Komal Patil-Sisodia: They are not the disease itself.
• 4:32
  Dr. Komal Patil-Sisodia: The new name tells a completely different story.
• 4:35
  Dr. Komal Patil-Sisodia: Let's take it word by word.
• 4:37
  Dr. Komal Patil-Sisodia: Polyendocrine.
• 4:39
  Dr. Komal Patil-Sisodia: This means multiple interacting hormonal disturbances, not one rogue hormone, a system-level disruption.
• 4:48
  Dr. Komal Patil-Sisodia: This means there are multiple interacting hormonal disturbances, not just one rogue hormone.
• 4:54
  Dr. Komal Patil-Sisodia: It is a system-level disruption that involves insulin, androgens, and neuroendocrine signaling that's all working against each other.
• 5:03
  Dr. Komal Patil-Sisodia: Metabolic.
• 5:04
  Dr. Komal Patil-Sisodia: This is the word that changes everything clinically.
• 5:08
  Dr. Komal Patil-Sisodia: Insulin resistance, elevated risk for type 2 diabetes, high cholesterol, cardiovascular risk, And weight changes and dysregulation are not side effects of this condition or coincidences.
• 5:20
  Dr. Komal Patil-Sisodia: They are core features, and we've never talked about that before.
• 5:24
  Dr. Komal Patil-Sisodia: Ovarian dysfunction, which is partially the disrupted follicle development and the disturbance in ovulation, still remain a defining feature.
• 5:33
  Dr. Komal Patil-Sisodia: But the ovary is just one part of the story.
• 5:35
  Dr. Komal Patil-Sisodia: It's not the whole story anymore, which is where it really makes a difference.
• 5:40
  Dr. Komal Patil-Sisodia: And what they removed was the term polycystic, and that word has been misdirecting care for generations.
• 5:48
  Dr. Komal Patil-Sisodia: Before we go any further, though, I want to address something that I know is already on the minds of clinicians and patients alike.
• 5:54
  Dr. Komal Patil-Sisodia: The diagnostic criteria did not change.
• 5:57
  Dr. Komal Patil-Sisodia: I had one person comment on one of my posts about PMOS.
• 6:01
  Dr. Komal Patil-Sisodia: PMOS should just stand for Pissing Me Off Syndrome because nothing really changed.
• 6:07
  Dr. Komal Patil-Sisodia: So I will address that this is a name change, not a diagnostic overhaul.
• 6:11
  Dr. Komal Patil-Sisodia: The Rotterdam criteria, which is the framework we use to diagnose this condition and requires two of the three things to be true, still includes irregular ovulation, meaning irregular periods, clinical or biochemical androgen excess, meaning high levels of testosterone or DHEAS, and polycystic ovarian morphology on ultrasound.
• 6:34
  Dr. Komal Patil-Sisodia: If you were diagnosed with PCOS under the existing criteria, that diagnosis is valid.
• 6:39
  Dr. Komal Patil-Sisodia: You have PMOS.
• 6:40
  Dr. Komal Patil-Sisodia: Nothing about your clinical picture needs to be readdressed.
• 6:45
  Dr. Komal Patil-Sisodia: What changed is the language we use to describe what you have.
• 6:49
  Dr. Komal Patil-Sisodia: Language that finally reflects the full biologic reality of the condition rather than just one narrow, inaccurate feature of it.
• 6:56
  Dr. Komal Patil-Sisodia: The World Health Organization estimates that seventy percent of people with this condition are currently undiagnosed.
• 7:04
  Dr. Komal Patil-Sisodia: Seventy percent, my mind is blown.
• 7:06
  Dr. Komal Patil-Sisodia: That is not a testing failure.
• 7:08
  Dr. Komal Patil-Sisodia: That is a framing failure, and it plays out differently depending on where a woman is in her hormonal life.
• 7:16
  Dr. Komal Patil-Sisodia: So let's start with the eras now.
• 7:19
  Dr. Komal Patil-Sisodia: Adolescence is what I call the eras of missed beginnings when it pertains to PMOS.
• 7:25
  Dr. Komal Patil-Sisodia: Adolescence is what I refer to as the era of missed beginnings, and this is where the real damage often starts, quietly, plainly in sight.
• 7:37
  Dr. Komal Patil-Sisodia: Think about what puberty looks like for a young woman who has PMOS but doesn't know it yet.
• 7:41
  Dr. Komal Patil-Sisodia: Her periods are irregular from the start, but she's told that's normal in the first few years after her period.
• 7:48
  Dr. Komal Patil-Sisodia: Her skin breaks out, but she's told that's just teenage acne.
• 7:52
  Dr. Komal Patil-Sisodia: She starts gaining weight, especially around her midsection, even though her diet hasn't changed.
• 7:58
  Dr. Komal Patil-Sisodia: She has hair growing in places that feel wrong and thinning in places that feel frightening.
• 8:04
  Dr. Komal Patil-Sisodia: Her mood is volatile in ways that go beyond typical adolescent emotional development.
• 8:10
  Dr. Komal Patil-Sisodia: And what does she hear?
• 8:12
  Dr. Komal Patil-Sisodia: Almost universally,"Give it time.
• 8:14
  Dr. Komal Patil-Sisodia: It'll regulate.
• 8:15
  Dr. Komal Patil-Sisodia: Here's the birth control pill." Which I want to be clear, I am not opposed to hormonal contraception in adolescents.
• 8:22
  Dr. Komal Patil-Sisodia: It can be an appropriate tool for management of PMOS.
• 8:26
  Dr. Komal Patil-Sisodia: But when it's handed to a teenager without any investigation into why her cycles are irregular, without any metabolic workup, without any conversation about insulin resistance or androgen excess, it becomes a lid on a pot that's still boiling.
• 8:43
  Dr. Komal Patil-Sisodia: The symptoms quiet down, the underlying condition continues to progress, and the diagnosis gets delayed by years, sometimes a decade.
• 8:54
  Dr. Komal Patil-Sisodia: And the diagnosis gets delayed by years, sometimes a decade.
• 8:58
  Dr. Komal Patil-Sisodia: Adolescence is genuinely tricky for PMOS diagnosis because there are some features we use in adults that overlap with normal puberty, irregular cycles, mild acne, follicular patterns on ultrasound.
• 9:11
  Dr. Komal Patil-Sisodia: The international guidelines actually recommend waiting at least two years after the first period before making a formal diagnosis and using more conservative criteria in adolescence.
• 9:21
  Dr. Komal Patil-Sisodia: That is appropriate caution.
• 9:24
  Dr. Komal Patil-Sisodia: But wait and see without metabolic surveillance is not the same as appropriate monitoring.
• 9:30
  Dr. Komal Patil-Sisodia: A teenager who has visible signs of insulin resistance, acanthosis nigricans, which is that velvety darkening of the skin at the neck and the underarms, fasting glucose trends that are moving in the wrong direction, weight gain that is not responding to any reasonable lifestyle efforts, deserves investigation, not reassurance alone.
• 9:50
  Dr. Komal Patil-Sisodia: And here's what's at stake.
• 9:51
  Dr. Komal Patil-Sisodia: We now know that early treatment of insulin resistance can restore spontaneous ovulation.
• 9:57
  Dr. Komal Patil-Sisodia: It can reduce androgen excess.
• 9:59
  Dr. Komal Patil-Sisodia: It can meaningfully change the metabolic trajectory of this condition before it compounds through decades of missed care.
• 10:06
  Dr. Komal Patil-Sisodia: The window in adolescence is not a window that you just wait through.
• 10:10
  Dr. Komal Patil-Sisodia: It's a window that you can act in, and the word metabolic in the new name change And the word metabolic in the new name changes what gets asked in that adolescent visit.
• 10:22
  Dr. Komal Patil-Sisodia: It changes what a pediatrician or adolescent gynecologist is trained to look for.
• 10:26
  Dr. Komal Patil-Sisodia: For the teenage girl sitting in an exam room right now being handed a prescription without a workup, she deserves better, And the new name is the first step in getting her that.
• 10:37
  Dr. Komal Patil-Sisodia: In the next era, which is the reproductive years, this is what I call the era of diagnosis and distraction.
• 10:43
  Dr. Komal Patil-Sisodia: For most women, the reproductive years in the twenties and thirties are when PMOS finally gets a name, but often only because of one thing, trouble getting pregnant.
• 10:54
  Dr. Komal Patil-Sisodia: And here is my clinical frustration with that reality.
• 10:58
  Dr. Komal Patil-Sisodia: By the time a woman is sitting in a fertility clinic getting this diagnosis, she may have had over a decade of symptoms that were dismissed or attributed to something else.
• 11:09
  Dr. Komal Patil-Sisodia: She's been managing her irregular cycles, often on hormonal contraception that is masking them.
• 11:15
  Dr. Komal Patil-Sisodia: She's been managing weight changes without adequate metabolic support.
• 11:19
  Dr. Komal Patil-Sisodia: She has been possibly living with anxiety or depression that was treated as a primary psychiatric condition, when in fact it was a neurobiologic expression of this underlying hormone disorder.
• 11:34
  Dr. Komal Patil-Sisodia: And the diagnosis finally arrives, but it arrives in a fertility context.
• 11:38
  Dr. Komal Patil-Sisodia: So the conversation centers almost entirely on ovulation induction, IVF protocols, and getting pregnant.
• 11:46
  Dr. Komal Patil-Sisodia: And those are critically important conversations, but they're not the whole conversation.
• 11:51
  Dr. Komal Patil-Sisodia: What about insulin resistance that has been driving this for years?
• 11:54
  Dr. Komal Patil-Sisodia: What about the cholesterol patterns?
• 11:56
  Dr. Komal Patil-Sisodia: What about the cardiovascular risk that the 2026 American College of Cardiology and American Heart Association dyslipidemia guidelines formally recognize as being made worse by conditions like PMOS?
• 12:09
  Dr. Komal Patil-Sisodia: What about the cardiovascular risk that the twenty twenty-six American College of Cardiology and American Heart Association dyslipidemia guidelines now formally recognize as being amplified by conditions like PMOS, which really make it an enhancer of cardiovascular risk?
• 12:26
  Dr. Komal Patil-Sisodia: What about the fact that pregnancy in a woman with unoptimized PMOS carries higher risks for gestational diabetes, for preeclampsia, and preterm birth?
• 12:37
  Dr. Komal Patil-Sisodia: All of these risks which can be meaningfully reduced with preconceptual metabolic care.
• 12:42
  Dr. Komal Patil-Sisodia: The fertility conversation and the metabolic conversation are not separate, in my opinion, and they should never be treated as if they are.
• 12:50
  Dr. Komal Patil-Sisodia: And beyond fertility, this is also the era where women with PMOS are in their peak professional years, carrying enormous cognitive and physical loads while they're managing things like fatigue, brain fog, mood instability, and weight struggles that can carry real stigma for them.
• 13:10
  Dr. Komal Patil-Sisodia: The old name contributed to that stigma in a specific way.
• 13:14
  Dr. Komal Patil-Sisodia: By framing this as a reproductive disorder, it implicitly told women that their problems were about their ovaries and not about a serious systemic condition that deserves the same clinical attention and social accommodation that we extend to diabetes and heart disease.
• 13:30
  Dr. Komal Patil-Sisodia: The word metabolic in PMOS changes that framing.
• 13:34
  Dr. Komal Patil-Sisodia: This is not a fertility problem with extra symptoms.
• 13:37
  Dr. Komal Patil-Sisodia: This is a metabolic condition with reproductive implications, and that reframe matters in the exam room.
• 13:43
  Dr. Komal Patil-Sisodia: It matters how a woman understands and advocates for herself, and it matters tremendously in how the medical system responds to her.
• 13:53
  Dr. Komal Patil-Sisodia: And it matters enormously in how the medical system responds to her.
• 13:58
  Dr. Komal Patil-Sisodia: The next era, perimenopause, is the era that nobody warns any woman about, unfortunately, or hasn't been for the last two decades.
• 14:07
  Dr. Komal Patil-Sisodia: Now we get to the era that is one that I find particularly interesting, and the one where I think the name change has some of the most profound and most underappreciated implications, perimenopause.
• 14:20
  Dr. Komal Patil-Sisodia: For a woman with PMOS, perimenopause is where the metabolic picture often intensifies, and almost no one is prepared for it because no one connects the dots across her hormonal life.
• 14:31
  Dr. Komal Patil-Sisodia: And here's what happens physiologically.
• 14:34
  Dr. Komal Patil-Sisodia: As ovarian function begins to decline, the hormonal support or scaffolding that was providing some structure begins to shift.
• 14:43
  Dr. Komal Patil-Sisodia: Estrogen levels are more variable.
• 14:45
  Dr. Komal Patil-Sisodia: The neuroendocrine regulation of LH and FSH, which are driving production of estrogen, will change.
• 14:52
  Dr. Komal Patil-Sisodia: And for women with underlying insulin resistance, this transition often brings on worsening metabolic features.
• 15:00
  Dr. Komal Patil-Sisodia: There's accelerated weight changes, particularly what we call that visceral fat that you gain around the middle, higher blood sugars, increasingly abnormal cholesterol, rising blood pressure.
• 15:15
  Dr. Komal Patil-Sisodia: And at the same time, she is experiencing classic perimenopausal symptoms, hot flashes or vasomotor symptoms, sleep disruption, cognitive changes, mood dysregulation, urogenital changes.
• 15:31
  Dr. Komal Patil-Sisodia: And because she's already been living with PMOS symptoms for decades, the clinical picture is genuinely complex.
• 15:39
  Dr. Komal Patil-Sisodia: What is PMOS?
• 15:40
  Dr. Komal Patil-Sisodia: What is perimenopause?
• 15:41
  Dr. Komal Patil-Sisodia: What is the interaction between the two?
• 15:44
  Dr. Komal Patil-Sisodia: The answer is all of it is connected.
• 15:47
  Dr. Komal Patil-Sisodia: The answer is all of it is connected.
• 15:49
  Dr. Komal Patil-Sisodia: The same polyendocrine dysregulation that drives PMOS interacts with all of the hormonal shifts of menopause transition in ways that we're still actively studying.
• 16:00
  Dr. Komal Patil-Sisodia: And here's something that trips up a lot of women, and frankly, a lot of clinicians.
• 16:05
  Dr. Komal Patil-Sisodia: Some women with PMOS actually experience their cycles becoming more regular in their thirties and early forties.
• 16:12
  Dr. Komal Patil-Sisodia: Their symptoms get quiet.
• 16:14
  Dr. Komal Patil-Sisodia: They may feel like they've, quote, outgrown the diagnosis, but they haven't.
• 16:19
  Dr. Komal Patil-Sisodia: The metabolic The metabolic dysfunction is still present, and perimenopause will often surface it again more loudly and in new ways.
• 16:30
  Dr. Komal Patil-Sisodia: This is also where the name change will matter enormously for research, because right now we have relatively little data on PMOS across the menopausal transition.
• 16:40
  Dr. Komal Patil-Sisodia: The old framing, cysts and fertility, meant that research funding gravitated towards reproductive-aged women.
• 16:47
  Dr. Komal Patil-Sisodia: Metabolic in the name demands longitudinal research.
• 16:50
  Dr. Komal Patil-Sisodia: What happens to cardiometabolic risk as these women age through the transition?
• 16:55
  Dr. Komal Patil-Sisodia: How does hormone therapy interact with underlying insulin resistance and androgen patterns in PMOS?
• 17:02
  Dr. Komal Patil-Sisodia: How do we build a metabolic optimization plan that will bridge that reproductive care into midlife seamlessly?
• 17:09
  Dr. Komal Patil-Sisodia: These are questions that should have been asked for decades.
• 17:12
  Dr. Komal Patil-Sisodia: The new name creates an urgency for us to finally answer them.
• 17:16
  Dr. Komal Patil-Sisodia: And then menopause and beyond, the era the name change protects.
• 17:22
  Dr. Komal Patil-Sisodia: When we arrive at menopause, the ovarian story is largely over.
• 17:26
  Dr. Komal Patil-Sisodia: The follicles, the anovulatory cycles, that chapter has closed.
• 17:30
  Dr. Komal Patil-Sisodia: And under the old framing, you might assume, and a lot of women were told that, polycystic ovarian syndrome closes with it.
• 17:38
  Dr. Komal Patil-Sisodia: It doesn't.
• 17:39
  Dr. Komal Patil-Sisodia: The metabolic story does not end at menopause.
• 17:42
  Dr. Komal Patil-Sisodia: In fact, for women with PMOS, the post-menopausal years may represent the period of highest cardiovascular risk, risk that has been building for decades without adequate clinical attention because no one was framing this as a lifelong metabolic condition.
• 17:59
  Dr. Komal Patil-Sisodia: We know that women with PMOS have elevated rates of insulin resistance, type two diabetes, high cholesterol, hypertension, long before menopause arrives.
• 18:10
  Dr. Komal Patil-Sisodia: And the twenty twenty-six ACC and AHA dyslipidemia guideline now formally recognizes reproductive and hormonal conditions as cardiovascular risk enhancers, meaning a woman's history of PMOS should be actively informing her lifetime cardiovascular risk assessment.
• 18:28
  Dr. Komal Patil-Sisodia: It should not be a footnote in an old OB chart that gets left behind when she transitions out of reproductive care.
• 18:35
  Dr. Komal Patil-Sisodia: And yet, how many post-menopausal women are sitting in an internist or cardiologist office with no one connecting their current metabolic profile to a hormonal condition that they were diagnosed with thirty years ago and told was, quote,"about their fertility"?
• 18:50
  Dr. Komal Patil-Sisodia: This is the same generational harm of the old name, polycystic ovarian syndrome.
• 18:57
  Dr. Komal Patil-Sisodia: By the time the ovaries are out of the picture, the name implies the condition is, too.
• 19:02
  Dr. Komal Patil-Sisodia: PMOS makes clear that it isn't.
• 19:05
  Dr. Komal Patil-Sisodia: Metabolic does not have an expiration date.
• 19:09
  Dr. Komal Patil-Sisodia: So what does the name actually change?
• 19:11
  Dr. Komal Patil-Sisodia: I want to land this where I started, with the name itself.
• 19:14
  Dr. Komal Patil-Sisodia: Polyendocrine metabolic, polyendocrine metabolic ovarian syndrome.
• 19:22
  Dr. Komal Patil-Sisodia: In adolescence, polyendocrine tells a clinician,"Look at the whole hormonal system.
• 19:27
  Dr. Komal Patil-Sisodia: Don't just hand her a pill and send her home.
• 19:29
  Dr. Komal Patil-Sisodia: Look deeper." In the reproductive years, metabolic tells a clinician,"This woman's fertility struggles exist inside of a metabolic context.
• 19:39
  Dr. Komal Patil-Sisodia: Don't treat the ovulation without treating the insulin resistance underneath it." In perimenopause, polyendocrine metabolic tells a clinician this transition is going to be complex.
• 19:51
  Dr. Komal Patil-Sisodia: She needs a long-term plan, not symptom by symptom patches.
• 19:56
  Dr. Komal Patil-Sisodia: In menopause and beyond, metabolic tells the clinician this story is not over.
• 20:01
  Dr. Komal Patil-Sisodia: The ovarian chapter closed, but the metabolic chapter is still being written, and it has cardiovascular consequences that require attention for the rest of her life.
• 20:11
  Dr. Komal Patil-Sisodia: One name, four eras, a completely different clinical posture at every stage.
• 20:16
  Dr. Komal Patil-Sisodia: That's why this name change matters.
• 20:19
  Dr. Komal Patil-Sisodia: For the women listening who have lived this, who spent years being dismissed, handed birth control pills without a workup, told to lose weight without being given the metabolic tools to actually do it, told their symptoms were-- For the women listening who have lived this, who spent years being dismissed, handed birth control pills without a workup, told to lose weight without being given the metabolic tools to actually do it, told their symptoms were anxiety or stress or just part of being a woman, I want you to hear this clearly.
• 20:50
  Dr. Komal Patil-Sisodia: You were not wrong about your body.
• 20:53
  Dr. Komal Patil-Sisodia: The name was wrong about your condition.
• 20:56
  Dr. Komal Patil-Sisodia: So here's what I want you to do with this.
• 20:58
  Dr. Komal Patil-Sisodia: If you have a PMOS diagnosis, or if you've suspected you might, know that your symptoms across your entire hormonal life are connected.
• 21:08
  Dr. Komal Patil-Sisodia: They are not separate, unrelated problems.
• 21:10
  Dr. Komal Patil-Sisodia: They are expressions of one underlying endocrine and metabolic condition, and you deserve care that addresses all of it at every stage.
• 21:20
  Dr. Komal Patil-Sisodia: If you are post-menopausal and have a history of PCOS, do not let that diagnosis stay in the past.
• 21:27
  Dr. Komal Patil-Sisodia: Bring it into every clinical conversation.
• 21:31
  Dr. Komal Patil-Sisodia: Ask about your cardiovascular risk assessment.
• 21:33
  Dr. Komal Patil-Sisodia: Ask whether lipoprotein little A has been checked or apolipoprotein B has been checked.
• 21:38
  Dr. Komal Patil-Sisodia: It's now Class one universal screening in the twenty twenty-six guidelines.
• 21:43
  Dr. Komal Patil-Sisodia: Ask about your glucose trends, your lipid panel, your blood pressure patterns.
• 21:48
  Dr. Komal Patil-Sisodia: Your PMOS history is clinically relevant today, not just in the past.
• 21:53
  Dr. Komal Patil-Sisodia: And if you're a clinician listening to this, this is our moment.
• 21:57
  Dr. Komal Patil-Sisodia: The name has changed.
• 21:59
  Dr. Komal Patil-Sisodia: Now let's make sure that the care changes with it.
• 22:02
  Dr. Komal Patil-Sisodia: Every hormonal era deserves a clinician who's asking the right questions, not just the ones the old name suggested.
• 22:09
  Dr. Komal Patil-Sisodia: That's what I'm here to do.
• 22:11
  Dr. Komal Patil-Sisodia: That's what this show is for.
• 22:12
  Dr. Komal Patil-Sisodia: I'm Dr.
• 22:13
  Dr. Komal Patil-Sisodia: Komal Patil-Sisodia.
• 22:14
  Dr. Komal Patil-Sisodia: This is Clearly Hormonal.
• 22:15
  Dr. Komal Patil-Sisodia: And if this episode resonated, please share it.
• 22:18
  Dr. Komal Patil-Sisodia: Send it to the woman in your life who's been searching for answers.
• 22:21
  Dr. Komal Patil-Sisodia: Send it to your doctor, and leave a review so more women can find this podcast.
• 22:26
  Dr. Komal Patil-Sisodia: Thank you so much for being here, and I'll see you on the next episode.